News

Press Release

Go to Topics

Back number

2020

Sysmex Obtains Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent
- Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800 - (PDF:170KB)
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- The Content Presented at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference - (PDF:182KB)
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2021 (PDF:438KB)
Sysmex Announces Financial Forecast for the Fiscal Year Ending March 31, 2021 (PDF:83KB)
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- Presenting the Most Recent Data at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference - (PDF:120KB)
Sysmex Applies for Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent
- Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800 - (PDF:130KB)
Medicaroid received Japanese regulatory approval for the “hinotori™ Surgical Robot System”, the first made-in-Japan robotic assisted surgery system
Collaboration of Medicaroid, Kawasaki Heavy Industries and Sysmex for the business of the "hinotori™ Surgical Robot System", a robotic assisted surgery system (PDF:389KB)
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2021 (PDF:433KB)
Sysmex Announces Dividend Forecast for the Fiscal Year Ending March 31, 2021 (PDF:102KB)
Insurance Coverage Received for Liquid Biopsy RAS Gene Mutation Testing for Colorectal Cancer Using High-Sensitivity Digital PCR (PDF:186KB)
Sysmex Launches OncoGuide™ NET Expert Panel Support System in Cancer Genome Profiling
- Supporting the Establishment of a System for Efficient Cancer Genomic Medicine - (PDF:151KB)
Sysmex Launches Lab Assay Service for Research on Cytokines Related to the Novel Coronavirus (SARS-CoV-2)
- Aiming to Monitor the Risk of Increasing Severity and Treatment Effects in Clinical Applications - (PDF:326KB)
Sysmex Launches New Products in the Hemostasis Field: Automated Blood Coagulation Analyzers CN-6500/CN-3500
- Using Chemiluminescence Enzyme Immunoassay to Enhance Testing Workflow Efficiency - (PDF:188KB)
The National Cancer Center, the National Center for Global Health and Medicine, and Sysmex Corporation Evaluate a SARS-CoV-2 Antibody Test with Support from the Japan Health Research Promotion Bureau
- Performance Report on an Antibody Detection Reagent Using Clinical Specimens - (PDF:314KB)
The City of Kobe, Kobe City Medical Center General Hospital, and Sysmex Corporation Working to Launch from Kobe the Clinical Implementation of a New Test for the Novel Coronavirus
- Collaborating with Medical Institutions of the Foundation for Biomedical Research and Innovation at Kobe to Strengthen Measures Allowing Early-Stage Diagnosis and Prediction of Severity - (PDF:171KB)
Sysmex to Launch Novel Coronavirus (SARS-CoV-2) Antibody Lab Assay Service and Antibody Measurement Reagents (for Research)
- Using the HISCL™-5000/HISCL™-800 Fully Automated Immunoassay Systems to Realize SARS-CoV-2 Antibody Detection - (PDF:150KB)
Sysmex Obtains First Marketing Approval in Japan for the Automated Hematology Analyzer XN-31 as a Class III Specially Controlled Medical Device to Diagnose Malaria
- For Use as a Measure against Imported Infectious Diseases in Japan and Accelerating its Introduction to the Asian and African Markets - (PDF:178KB)
Our Views and Policy regarding Investment Unit Reduction (PDF:94KB)
Sysmex Launches Flow Cytometer XF-1600 in North America
- Contribute to higher efficiency and standardization of the laboratory workflow for FCM testing - (PDF:180KB)
The Use of Saliva in PCR Tests for the Novel Coronavirus
- Expanding the Scope of Sample Types - (PDF:168KB)
Sysmex and OPTiM Jointly Establish New Company to Plan, Develop and Operate Medical AI and IoT Open Platforms and Digital Transformation Solutions (PDF:153KB)
Information about Litigation against Sysmex Corporation and its Subsidiary (PDF:105KB)
Sysmex Donates ¥30 Million to Kobe City Support Fund for Medical Professionals to Support COVID-19 Countermeasures (PDF:107KB)
The City of Kobe, Sysmex and SRL Configure and Begin Operating a PCR Testing System for COVID-19 within the Kobe Biomedical Innovation Cluster (PDF:105KB)
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2020 (PDF:234KB)
Sysmex Announces Changes from Financial Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2020 (PDF:46KB)
Announcement of Executive Change (PDF:137KB)
Advanced Medical Care Approval for Cancer Gene Panel Testing at the Time of Initial Treatment
- Prospective Study to Assess the Feasibility and Clinical Utility of Comprehensive Genomic Profiling at the Time of Initial Treatment of Patients with Solid Tumors - (PDF:122KB)
Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method)
- Aiming for early introduction of test kits for in vitro diagnostic medical devices in medical institutions - (PDF:183KB)
Announcement of Organizational and Personnel Changes (PDF:376KB)
Sysmex to Introduce New Globally Consistent Job-Based HR Management System with the Aim of Realizing Sustainable Growth
Sysmex and the Kobe City Eye Hospital Sign a Comprehensive Collaboration Agreement
-Reinforcing Collaboration toward the Realization of Genomic Medicine in the Area of Ophthalmic Disorders- (PDF:120KB)
Sysmex Presents Academic Report Related to the Clinical Utility of RAS Gene Mutation Testing for Colorectal Cancer Using Liquid Biopsy
Details of Report on Clinical Utility of OncoBEAM™ RAS CRC Kit presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020) (PDF:130KB)
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2020 (PDF:506KB)
Sysmex and RIKEN Innovation Sign a Comprehensive Collaborative Agreement
Sysmex Invests in Astrego Diagnostics with a View to Developing New Urinalysis Solutions for the Primary Care Business
Sysmex Receives Regulatory Approval in China of an in Vitro Diagnostic Reagent to Help Diagnose Breast Cancer Lymph Node Metastasis Using the OSNA™ Method
-Aiming to Introduce a System to Test for Breast Cancer Lymph Node Metastasis into the Chinese Market-
Sysmex Launches Gene Testing Kit for Blood Cancer (ipsogen JAK2 DX Reagent)
First Insurance Coverage in Japan for JAK2V617F Gene Mutation Testing for Myeloproliferative Neoplasms